Liposomal Drug Delivery Devices Market Report 2026

Liposomal Drug Delivery Devices Market Overview

• Liposomal Drug Delivery Devices market size has reached to $5.34 billion in 2025 • Expected to grow to $9.49 billion in 2030 at a compound annual growth rate (CAGR) of 12.1% • Growth Driver: Global Increase In Cancer Cases Fuels Growth Of Liposomal Drug Delivery Devices Market • Market Trend: Innovative Liposomal Drug Delivery Enhances Patient Compliance And Oncology Treatment Options • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Liposomal Drug Delivery Devices Market?

Liposomal drug delivery devices are microscopic colloidal spheres that are used to deliver drug molecules to the site of action. The main types of liposomal drug delivery devices are liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Liposomal doxorubicin is a kind of chemotherapy drug known as anthracycline wrapped up in a liposome. It slows or stops the increase of cancer cells by blocking an enzyme called topoisomerase. The applications included are fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy that are used in hospitals, diagnostic centers, ambulatory surgery centers/clinics, and others.

What Is The Liposomal Drug Delivery Devices Market Growth Forecast?

The liposomal drug delivery devices market size is expected to see rapid growth in the next few years. It will grow to $9.49 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing demand for targeted cancer treatments, expansion of personalized medicine approaches, growing adoption of advanced drug delivery platforms, rising investments in biologics and vaccines, increasing focus on reducing drug toxicity. Major trends in the forecast period include increasing adoption of targeted drug delivery systems, rising use of pegylated liposomal formulations, growing application in oncology therapies, expansion of liposomal vaccines and antifungals, enhanced focus on controlled drug release.

Global Liposomal Drug Delivery Devices Market Segmentation

1) By Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Other Types 2) By Application: Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy 3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Other End Users Subsegments: 1) By Liposomal Doxorubicin: Conventional Liposomal Doxorubicin, PEGylated Liposomal Doxorubicin 2) By Liposomal Paclitaxel: Conventional Liposomal Paclitaxel, PEGylated Liposomal Paclitaxel 3) By Liposomal Amphotericin B: Conventional Liposomal Amphotericin B, PEGylated Liposomal Amphotericin B 4) By Other Types: Liposomal Irinotecan, Liposomal Vincristine, Liposomal Cytarabine

What Is The Driver Of The Liposomal Drug Delivery Devices Market?

The rise in the number of cancer cases across the globe is expected to propel the growth of the liposomal drug delivery devices market going forward. Cancer refers to a broad group of diseases characterized by the uncontrolled growth and spread of abnormal cells; the increasing incidence reflects the combined impact of population aging, environmental risk factors, and lifestyle changes. As cancer prevalence grows, there is a stronger demand for advanced, targeted therapies such as liposomal formulations that can improve drug delivery, reduce systemic toxicity, and enhance treatment efficacy. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, an estimated 20?million new cancer cases occurred in 2022, with projections to reach 35?million by 2050, representing a 77% increase. Therefore, the rising global burden of cancer is driving the growth of the liposomal drug delivery devices industry.

Key Players In The Global Liposomal Drug Delivery Devices Market

Major companies operating in the liposomal drug delivery devices market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Gilead Sciences Inc., Ipsen SA, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd., Nanomerics Ltd., Luye Pharma Group Ltd., Leadiant Biosciences Inc., Pacira Biosciences Inc., Nippon Kayaku Co. Ltd., Celsion Corporation, Acrotech Biopharma Inc., Aphios Pharma LLC, CytImmune Sciences Inc., NanoSphere Health Sciences Inc., Cel-Sci Corporation, Lipoid GmbH, Liposome Company Inc., Liposome Research Days Corporation, Taiwan Liposome Company

Global Liposomal Drug Delivery Devices Market Trends and Insights

Major companies operating in the liposomal drug delivery market are introducing innovative products, such as hydrochloride liposome injection, to gain a competitive edge in the market. Researchers have been working on developing liposomal nanostructures that can improve patient compliance by allowing less frequent doses while maintaining efficacy. For instance, in August 2024, Lupin Ltd., an India-based pharma company, launched Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL). The Doxorubicin Hydrochloride Liposome Injection had an estimated annual sales figure of approximately USD 40.9 million in the U.S. market as of June 2024. This positions Lupin strategically within the oncology segment as it expands its portfolio to include this important cancer treatment option. Lupin's commitment to improving patient health outcomes is evident through this launch, as it aims to provide effective treatment alternatives in a competitive pharmaceutical landscape.

What Are Latest Mergers And Acquisitions In The Liposomal Drug Delivery Devices Market?

In October 2024, Liquidia Corporation, a US-based provider of biopharmaceutical therapies for rare cardiopulmonary diseases, expanded its partnership with Pharmosa Biopharm to advance the development of L606. Through this expanded collaboration, Liquidia aims to strengthen its capabilities in liposomal drug delivery by integrating Pharmosa’s proprietary liposomal formulation and inhalation device technologies to co-develop L606, a sustained-release inhaled treprostinil therapy. Pharmosa Biopharm is a Taiwan-based biotechnology company focused on developing innovative drugs using advanced liposomal drug delivery systems and inhalation platforms

Regional Outlook

North America was the largest region in the liposomal drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Liposomal Drug Delivery Devices Market?

The liposomal drug delivery devices market consists of sales of instruments such as liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.